These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20824151)

  • 1. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087.
    Fichtenbaum CJ; Yeh TM; Evans SR; Aberg JA
    J Clin Lipidol; 2010; 4(4):279-87. PubMed ID: 20824151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.
    Grandi AM; Nicolini E; Rizzi L; Caputo S; Annoni F; Cremona AM; Marchesi C; Guasti L; Maresca AM; Grossi P
    J Int AIDS Soc; 2014; 17(1):19004. PubMed ID: 25148829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients.
    Joshi PH; Miller PE; Martin SS; Jones SR; Massaro JM; D'Agostino RB; Kulkarni KR; Sponseller C; Toth PP
    AIDS; 2017 Apr; 31(7):965-971. PubMed ID: 28121706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy.
    Farnier M; Ducobu J; Bryniarski L
    Curr Med Res Opin; 2011 Nov; 27(11):2165-73. PubMed ID: 21973199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The fixed combination of pravastatin and fenofibrate: what can it provide?].
    Díaz Rodríguez Á
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():12-6. PubMed ID: 25043541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial.
    Balasubramanyam A; Coraza I; Smith EO; Scott LW; Patel P; Iyer D; Taylor AA; Giordano TP; Sekhar RV; Clark P; Cuevas-Sanchez E; Kamble S; Ballantyne CM; Pownall HJ
    J Clin Endocrinol Metab; 2011 Jul; 96(7):2236-47. PubMed ID: 21565796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.
    Dubé MP; Komarow L; Fichtenbaum CJ; Cadden JJ; Overton ET; Hodis HN; Currier JS; Stein JH;
    Clin Infect Dis; 2015 Sep; 61(5):840-9. PubMed ID: 25979307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial.
    Ihm SH; Chung WB; Lee JM; Hwang BH; Yoo KD; Her SH; Song WH; Chae IH; Park TH; Kim JH; Jeon DW; Cho BR; Kang SH; Park SD; Lee JB; Woo JT; Lee BW; Han KA; Won KH; Kim HS; Yu JM; Chung CH; Kim HJ; Cho HC; Seung KB
    Clin Ther; 2020 Oct; 42(10):2021-2035.e3. PubMed ID: 32891418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Indications for the combination of pravastatin and fenofibrate according to the type of dyslipidemia].
    Núñez-Cortés JM
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():31-4. PubMed ID: 25043545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.
    Albert MA; Danielson E; Rifai N; Ridker PM;
    JAMA; 2001 Jul; 286(1):64-70. PubMed ID: 11434828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
    Aberg JA; Zackin RA; Brobst SW; Evans SR; Alston BL; Henry WK; Glesby MJ; Torriani FJ; Yang Y; Owens SI; Fichtenbaum CJ;
    AIDS Res Hum Retroviruses; 2005 Sep; 21(9):757-67. PubMed ID: 16218799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
    Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
    J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy.
    Aguilar-Salinas CA; Hugh P; Barrett R; Pulai J; Zhu XL; Schonfeld G
    Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):72-82. PubMed ID: 9012640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Curr Med Res Opin; 2009 Aug; 25(8):1973-83. PubMed ID: 19555253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients.
    Farnier M; Taggart W; Dong Q; Lin J; Shah A; Brudi P
    J Clin Lipidol; 2011; 5(3):179-187. PubMed ID: 21600523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pravastatin on endothelial dysfunction in children with medium to giant coronary aneurysms due to Kawasaki disease.
    Duan C; Du ZD; Wang Y; Jia LQ
    World J Pediatr; 2014 Aug; 10(3):232-7. PubMed ID: 25124974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia.
    Li JJ; Li YS; Chu JM; Zhang CY; Wang Y; Huang Y; Chen J; Yuan JQ; Huang YL
    Clin Chim Acta; 2006 Apr; 366(1-2):269-73. PubMed ID: 16343471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.